Trials / Completed
CompletedNCT03075462
A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients
An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 98 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Fluzoparib is an oral potent, selective poly-ADP ribose polymerase-1 (PARP-1) and PARP-2 inhibitor; Apatinib is an oral selective vascular endothelial growth factor receptor (VEGFR) inhibitor. This open-label, dose finding phase I trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and to see how well these two drugs work together in the treatment of patients with recurrent ovarian cancer or triple negative breast cancer. The safety and efficacy of fluzoparib in combination with apatinib will be explored. Both dose escalation and dose expansion parts are included in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fluzoparib | Fluzoparib either at 40,60,80mg twice daily,capsule oral. |
| DRUG | Apatinib | Apatinib at 250mg once daily, tablet oral |
Timeline
- Start date
- 2017-03-09
- Primary completion
- 2021-08-22
- Completion
- 2021-12-13
- First posted
- 2017-03-09
- Last updated
- 2022-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03075462. Inclusion in this directory is not an endorsement.